companydata.dkcompanydata.dk

Incyte Biosciences Denmark ApS: Financial statements 2022

CVR: 35818790

Source: annual report 2022, Danish Business Authority

01/01/2022 – 31/12/2022

Incyte Biosciences Denmark ApS (CVR 35818790) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 5,556,640 and a net result of DKK 277,949 compared with DKK 268,531 the year before. That is an increase of 5.1% compared with the year before. Equity in the 2022 report amounted to DKK 1,223,888. The solvency ratio was 17.5%. The company had 4 employees in the financial year.

Gross Profit
DKK 5,556,640
Profit/Loss
DKK 277,949
Equity
DKK 1,223,888
Total Assets
DKK 6,991,154
Employees
4

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2022-5.6M278K1.2M4
2021-5.3M269K946K4
2020-5.4M150K677K3
2019-4.8M286K527K3
2018-3M87K241K2

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on Incyte Biosciences Denmark ApS

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2022

Incyte Biosciences Denmark ApS: The 2021 annual report is outApr 6, 2022

Incyte Biosciences Denmark ApS has published its annual report for 2021. Gross profit came to DKK 5,287,823, and the net result was DKK 268,531.

About Incyte Biosciences Denmark ApS

Incyte Biosciences Denmark ApS is a Danish company of the type Anpartsselskab based in Frederiksberg C, founded in 2014. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named ARIAD PHARMACEUTICALS (DENMARK) ApS. The management consists of Ebba Cecilia Bröms. The board consists of Lee Jason Heeson (chair) and Ebba Cecilia Bröms. The company is owned by Incyte Biosciences International Sàrl. The company has 4 employees (2026). In 2025, the company reported a gross profit of DKK 6,696,586 and a net result of DKK 361,151 compared with DKK 368,873 the year before. Equity in the 2025 report amounted to DKK 2,328,496.

Source: annual report 2025, Danish Business Authority